Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 12 | Rare Historical Photos

Blackbaud Touts AI Agents, Payments Growth and Buybacks at Baird Conference

Blackbaud (NASDAQ:BLKB) executives emphasized the company’s nonprofit software focus, artificial intelligence initiatives, payments opportunity and capital return strategy during a discussion hosted by Baird Senior Research Analyst Rob Oliver. Oliver described Blackbaud as a vertical software leade

MarketBeat

BlackLine Says AI Agents, Platform Pricing Can Reignite Revenue Growth

BlackLine (NASDAQ:BL) executives said the company is leaning on platform pricing, artificial intelligence and deeper enterprise adoption as it works to reaccelerate revenue growth, according to remarks at a William Blair conference session. Chair and CEO Owen Ryan described BlackLine as a “mission-

MarketBeat

CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?

CrowdStrike stock fell after beating earnings and raising guidance. Here's why investors may see the post-earnings selloff as a buying opportunity

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

From Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading

Check out these three stocks that insiders are buying and selling, including giants in oil and AI, as well as a small gene stock seeing huge swings.

MarketBeat

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s chief business officer

MarketBeat

MarketBeat Week in Review – 06/01 - 06/05

Stocks sold off sharply to end the week with money moving out of technology stocks and into many of the Dow components; inflation fears are rising.

MarketBeat

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart

MarketBeat

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

MarketBeat

Axon Enterprise Touts AI, Global Markets and Counter-Drone Demand as Growth Engines

Axon Enterprise (NASDAQ:AXON) President Josh Isner said the company continues to see durable growth opportunities across public safety, international markets, enterprise customers and new artificial intelligence products, speaking during a William Blair & Company fireside chat hosted by research

MarketBeat

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosi

MarketBeat

AeroVironment Sees Drone Demand Taking Off as Switchblade, Counter-Drone Capacity Expands

AeroVironment (NASDAQ:AVAV) executives told investors at William Blair’s 46th Annual Growth Stock Conference that the company sees expanding opportunities across drones, loitering munitions and counter-drone systems, while also emphasizing ongoing capacity investments tied to programs such as Switch

MarketBeat

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

MarketBeat

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

AI Server Earnings: Wall Street Sees One Clear Standout

AI server stocks put up eye-popping gains in May and early June, with Supermicro, Dell, and HPE seeing huge pops after their latest earnings.

MarketBeat

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

MarketBeat

Quanex Building Products Q2 Earnings Call Highlights

Quanex Building Products (NYSE:NX) reported a modest increase in fiscal second-quarter revenue but sharply lower earnings, as inflation in raw materials, freight and logistics weighed on margins and led the company to withhold reaffirmation of its prior full-year outlook. On the company’s earnings

MarketBeat

A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below

Lululemon isn't out of danger as its FQ1 release reveal new risks for investors. The stock price is moving lower and may enter freefal this summer.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

StealthGas Q1 Earnings Call Highlights

StealthGas (NASDAQ:GASS) reported higher first-quarter revenue and continued to emphasize its debt-free balance sheet, growing cash position and charter coverage during its first-quarter 2026 earnings call. Chairman Michael Jolliffe said revenue rose to $42.8 million in the quarter, up 2% from $42

MarketBeat

Saputo Q4 Earnings Call Highlights

Saputo (TSE:SAP) executives said the dairy processor ended fiscal 2026 with stronger margins, improved cash generation and a more focused portfolio, even as lower U.S. dairy commodity pricing weighed on reported revenue in the fourth quarter. On the company’s fourth-quarter earnings call, President

MarketBeat

ABM Industries Q2 Earnings Call Highlights

ABM Industries (NYSE:ABM) reported stronger second-quarter fiscal 2026 revenue growth and record first-half new sales bookings, while management maintained its full-year adjusted earnings outlook and said it expects a stronger margin performance in the second half of the year. President and Chief E

MarketBeat

G-III Apparel Group Q1 Earnings Call Highlights

G-III Apparel Group (NASDAQ:GIII) reported first-quarter fiscal 2027 results that exceeded its own expectations, as stronger gross margins and growth in its go-forward brand portfolio helped offset the planned loss of revenue tied to PVH brands. Chairman and Chief Executive Officer Morris Goldfarb

MarketBeat

Five Below Down 12% Post Earnings—Is the Selloff Overdone?

Five Below fell more than 13% after Q1 2026 earnings beat estimates, as cautious second-half guidance and tariff uncertainty overshadowed strong revenue and EPS results.

MarketBeat

Arrow Financial Highlights Profit Gains, Adirondack Bank Deal at Annual Meeting

Arrow Financial (NASDAQ:AROW) used its virtual annual meeting to highlight what executives described as a transformational 2025, including the first full year operating under the unified Arrow Bank brand, stronger profitability metrics and progress toward its planned acquisition of Adirondack Bank.

MarketBeat

Tuniu Q1 Earnings Call Highlights

Tuniu (NASDAQ:TOUR) reported higher first-quarter revenue and its fifth consecutive quarter of non-GAAP profitability, as management said China’s travel market continued to benefit from solid demand during the period, including support from the longest Chinese New Year holiday on record. Founder, C

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.